These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 17544389)

  • 1. Cross-reactivity of epoetin alfa and darbepoetin alfa with two immunochemiluminometric erythropoietin assays.
    Mongia SK; Roberts WL; Owen WE
    Clin Chim Acta; 2007 Aug; 383(1-2):184-5. PubMed ID: 17544389
    [No Abstract]   [Full Text] [Related]  

  • 2. The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum.
    Mytych DT; La S; Barger T; Ferbas J; Swanson SJ
    J Pharm Biomed Anal; 2009 Feb; 49(2):415-26. PubMed ID: 19135328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
    Pussell BA; Walker R;
    Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease.
    Roger SD; Suranyi MG; Walker RG; Disney A; Isbel NM; Kairaitis L; Pollock CA; Brown FG; Chow J; Truman MI; Ulyate KA;
    Curr Med Res Opin; 2008 Aug; 24(8):2181-7. PubMed ID: 18565240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.
    Allon M; Kleinman K; Walczyk M; Kaupke C; Messer-Mann L; Olson K; Heatherington AC; Maroni BJ
    Clin Pharmacol Ther; 2002 Nov; 72(5):546-55. PubMed ID: 12426518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X; Long SR; Marder WD; Sullivan SD; Kallich J
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ; Jacobson DR
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythropoietin claims monitoring policy: implications of the October 2006 update continuing.
    Messana T
    Nephrol Nurs J; 2006; 33(6):660-3; quiz 664-5. PubMed ID: 17219727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients.
    Nissenson AR; Swan SK; Lindberg JS; Soroka SD; Beatey R; Wang C; Picarello N; McDermott-Vitak A; Maroni BJ
    Am J Kidney Dis; 2002 Jul; 40(1):110-8. PubMed ID: 12087568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS; Rocconi RP; Kilgore LC; Barnes MN
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD; Cooper B
    Nephrology (Carlton); 2004 Aug; 9(4):223-8. PubMed ID: 15363054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ; Glaspy JA; Adams JL; Mafilios MS; Wang SM; Viswanathan HN; Kallich JD
    J Med Econ; 2008; 11(2):199-213. PubMed ID: 19450080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of epoetin alfa and darbepoetin alfa biological activity under different administration schedules in normal mice.
    Sasu BJ; Hartley C; Schultz H; McElroy P; Khaja R; Elliott S; Egrie JC; Browne JK; Begley CG; Molineux G
    Acta Haematol; 2005; 113(3):163-74. PubMed ID: 15870486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
    Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS; Yee LK; Senecal FM; Charu V; Tomita D; Wallace J; Rossi G
    Oncologist; 2004; 9(6):696-707. PubMed ID: 15561813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of recombinant epoetin and darbepoetin alpha after subcutaneous administration in the horse.
    Lasne F; Popot MA; Varlet-Marie E; Martin L; Martin JA; Bonnaire Y; Audran M; de Ceaurriz J
    J Anal Toxicol; 2005; 29(8):835-7. PubMed ID: 16374944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes associated with conversion from epoetin alfa to darbepoetin alfa in hospitalized hemodialysis patients.
    Sarac E; Chikyarappa A; Sabol B; Gemmel D; Globe D; Barlev A; Audhya P
    Am J Nephrol; 2006; 26(6):571-8. PubMed ID: 17170523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.